"Renovo is the world leader in scar prevention and reduction research, developing pharmaceutical products to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments.
Our pipeline is extensive and includes four products in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical candidates.
There is an estimated multi-billion dollar global market for anti-scarring drugs, and Renovo aims to be first to market with a scar prevention pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need..."
renovo.com
With the announcement of a successful PII for Juvista (human recombinant TG beta 3) -
Message 22856801
- it could be time to take them seriously.
Time for a thread, anyhow. |
